Home » Stocks » SNCA

Seneca Biopharma, Inc. (SNCA)

Stock Price: $1.19 USD 0.08 (7.21%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
Market Cap 18.16M
Revenue (ttm) 13,520
Net Income (ttm) -13.89M
Shares Out 17.31M
EPS (ttm) -0.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $1.19
Previous Close $1.11
Change ($) 0.08
Change (%) 7.21%
Day's Open 1.09
Day's Range 1.05 - 1.20
Day's Volume 2,200,607
52-Week Range 0.50 - 2.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 1 month ago

GERMANTOWN, Md., Jan. 20, 2021 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need...

Benzinga - 1 month ago

Regeneron Pharmaceuticals (NASDAQ: REGN) shares are trading higher after the company announced an additional U.S. order to purchase 1.25 million doses of its COVID-19 antibody cocktail bringin...

Other stocks mentioned: JAGX, REGN
PRNewsWire - 2 months ago

NEW YORK, Dec. 23, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Buildingin New...

PRNewsWire - 2 months ago

NEW YORK, Dec. 18, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Seneca Biopharma, Inc. (NASDAQ: SNCA) and its board of directors concerning the ...

PRNewsWire - 2 months ago

NEW YORK, Dec. 17, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Seneca Biopharma, Inc. ("Sene...

Business Wire - 2 months ago

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Seneca Biopharma, Inc. (NASDAQ: SNCA) and Leading BioSciences, Inc. is fa...

PRNewsWire - 2 months ago

GERMANTOWN, Md., Dec. 15, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need...

PRNewsWire - 6 months ago

GERMANTOWN, Md., Aug. 13, 2020 /PRNewswire/ -- Seneca Biopharma, Inc.

PRNewsWire - 9 months ago

GERMANTOWN, Md., May 22, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need,...

PRNewsWire - 9 months ago

GERMANTOWN, Md., May 22, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq:SNCA), a clinical-stage biopharmaceutical company developing novel treatments for various diseases of high unmet me...

PRNewsWire - 9 months ago

GERMANTOWN, Md., May 15, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need,...

About SNCA

Seneca Biopharma, a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidates include NSI-189, a chemical entity, which has been complet... [Read more...]

Industry
Biotechnology
Founded
1996
CEO
Kenneth Carter
Employees
7
Stock Exchange
NASDAQ
Ticker Symbol
SNCA
Full Company Profile

Financial Performance

In 2019, SNCA's revenue was $15,394, a decrease of -94.08% compared to the previous year's $260,000. Losses were -$8.35 million, 69.6% more than in 2018.

Financial Statements